October 08, 2025 09:05 ET | Source: Silynxcom Ltd. Netanya, Israel, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Silynxcom Ltd. (NYSE…
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led…
Collaboration with Schools and Communities to Protect Children and Vulnerable Road Users In the compact and dynamic city-state of most…
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…
TOKYO, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) today announced that its subsidiary, MEDIROM…
73% of adults feel safe walking alone at night; wide gender and regional gaps remain WASHINGTON, Sept. 18, 2025 /PRNewswire/…
WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical…
LEUVEN, BELGIUM – The chances are you won’t have heard of it and will never have seen one of its…
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~…
Detroit, Aug. 23, 2025 (GLOBE NEWSWIRE) -- This press release is for informational purposes only. The content provided does not…
